Related Experiment Videos
Variability of Nt-proANP and C-ANP
G McDowell1, C Patterson, S Maguire
1Royal Victoria Hospital, Belfast, Queen's University of Belfast, UK.
European Journal of Clinical Investigation
|August 23, 2002
Summary
N-terminal pro-atrial natriuretic peptide (Nt-proANP) is less variable than atrial natriuretic peptide (C-ANP) in patients with chronic cardiac failure. This makes Nt-proANP more suitable for routine diagnostic and prognostic use in CCF patients.
Area of Science:
- Cardiology
- Biomarkers
- Medical Diagnostics
Background:
- Natriuretic peptides are crucial biomarkers for chronic cardiac failure (CCF).
- Assessing the variability of C-ANP and Nt-proANP is essential for determining their suitability in routine CCF management.
Purpose of the Study:
- To compare the measurement variability of C-ANP and Nt-proANP.
- To identify the more suitable natriuretic peptide for routine clinical use in CCF patients.
Main Methods:
- Studied ten males with compensated CCF and matched controls.
- Collected blood samples every 2 minutes for 90 minutes.
- Measured plasma C-ANP and Nt-proANP concentrations using radioimmunoassay.
Main Results:
- Both C-ANP and Nt-proANP levels were significantly elevated in CCF patients compared to controls.
- Similar patterns of peptide 'peaks' were observed for both C-ANP and Nt-proANP.
- Nt-proANP exhibited significantly lower variability (lower coefficient of variation) than C-ANP in both CCF patients and controls.
Conclusions:
- Nt-proANP demonstrates superior stability and lower variability compared to C-ANP.
- Nt-proANP is the preferred natriuretic peptide for routine diagnostic and prognostic applications in chronic cardiac failure.